Competition Law and Policy in the Japanese Pharmaceutical Sector

This book is the first to focus on competition law and policy in the Japanese pharmaceutical sector, covering drug regulations, trade practices, the Japanese Antimonopoly Act, innovation, intellectual property, and economic analyses. It provides a comprehensive overview of the industry, appealing to students, academics, pharmaceutical companies, and regulators.

Format: Hardback
Length: 245 pages
Publication date: 09 February 2022
Publisher: Springer Verlag, Singapore

This groundbreaking book is the first to delve into the intricate world of competition law and policy in the Japanese pharmaceutical sector. Comprising a collection of chapters authored and meticulously edited by esteemed academics who possess diverse perspectives on the industry, including economics, competition law, pharmaceutical regulations, and intellectual property law, this comprehensive volume offers a profound exploration of the complex dynamics at play within this vital industry.

The pharmaceutical industry, characterized by its global reach and intricate regulatory frameworks, garners significant attention from academics and policymakers alike. Drug laws, which vary significantly across countries, are influenced by diverse practices and industrial structures, creating a complex tapestry of regulations. The book begins by delving into the unique drug regulations and trade practices that are specific to Japan and its healthcare system. It then presents a comprehensive analysis of the Japanese Antimonopoly Act, highlighting its key provisions and notable cases involving it. Furthermore, the book delves into the current competition law issues that plague the Japanese pharmaceutical industry, shedding light on the challenges and opportunities that arise in this dynamic market.

In addition to its examination of regulatory frameworks, the book also explores the realm of innovation and intellectual property in the pharmaceutical sector. It conducts economic analyses of pharmaceutical regulations and drug discovery, providing valuable insights into the economic implications of these policies. The chapters include comparative studies on Japanese regulations versus those in the European Union and the United States, offering a comparative perspective on the regulatory landscape.

Japan, as one of the largest pharmaceutical markets in the world, presents a unique and fascinating landscape for those interested in pharmaceutical regulations. Recognizing the significance of this market, the book serves as a comprehensive resource for individuals seeking to gain a deeper understanding of the regulatory framework and its impact on the industry. Whether you are a student, academic, pharmaceutical company, regulator, or involved in real-world policy issues that encompass competition policy, intellectual property, and pharmaceutical regulation, this book offers invaluable insights and perspectives.

Chapter 11 of this remarkable book is graciously made available open access under a Creative Commons Attribution 4.0 International License via the link: link.springer.com. This allows for widespread access and dissemination of knowledge, fostering a greater understanding of the critical issues discussed in the book.

In conclusion, this groundbreaking book is a testament to the tireless efforts of the authors and editors who have brought together a wealth of knowledge and expertise in the field of competition law and policy in the Japanese pharmaceutical sector. It serves as a valuable resource for scholars, policymakers, industry professionals, and anyone with an interest in understanding the complex dynamics and challenges of this vital industry. By providing a comprehensive exploration of competition law, intellectual property, and pharmaceutical regulations, this book contributes to the ongoing discourse on shaping the future of healthcare and pharmaceuticals worldwide.

Weight: 571g
Dimension: 235 x 155 (mm)
ISBN-13: 9789811678134
Edition number: 1st ed. 2022